Stocklytics Platform
Asset logo for symbol KALV
KalVista Pharmaceuticals
KALV47
$11.34arrow_drop_down1.73%-$0.20
Asset logo for symbol KALV
KALV47

$11.34

arrow_drop_down1.73%
Key Stats
Open$11.61
Prev. Close$11.54
EPS-3.57
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range11.18
11.81
52 Week Range7.21
16.88
Ratios
Revenue-
EBITDA Margin %-
EPS-3.57
Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.89%
Last Dividend pay dateNov 22, 2016
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

KALV-
US Healthcare Sector-
US Market-
warning

KALV / Market

KALV lose to the US Market which returned 1.73% over the last twenty four hours.
warning

KALV / Healthcare Sector

KALV lose to the US Healthcare sector which returned 1.88% over the last twenty four hours.

KalVista Pharmaceuticals (KALV) Statistics

KalVista Pharmaceuticals Inc (KALV) is a pharmaceutical company that focuses on the discovery, development, and commercialization of small molecule protease inhibitors for the treatment of diseases with significant unmet need. The company is dedicated to improving the lives of patients through its innovative therapies. With a strong pipeline of drug candidates, KalVista Pharmaceuticals is well-positioned for future growth.
When it comes to valuation metrics, KalVista Pharmaceuticals Inc (KALV) stands out in the pharmaceutical sector. The company has a favorable price-to-earnings ratio and price-to-sales ratio compared to its peers. This indicates that KalVista Pharmaceuticals may be undervalued relative to its earnings and sales potential. Investors looking for a promising pharmaceutical stock should consider KalVista Pharmaceuticals as a potential investment opportunity.
add KalVista Pharmaceuticals  to watchlist

Keep an eye on KalVista Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has KalVista Pharmaceuticals (KALV) stock's performance compared to its sector and the market over the past year?

Over the past year, KalVista Pharmaceuticals (KALV) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 35.30%, KalVista Pharmaceuticals has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 71.47%, it has fallen short of the market average. This comparison highlights KalVista Pharmaceuticals 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of KalVista Pharmaceuticals (KALV) stock?

The PE ratio for KalVista Pharmaceuticals (KALV) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of KalVista Pharmaceuticals (KALV) stock?

The Earnings Per Share (EPS) for KalVista Pharmaceuticals (KALV), calculated on a diluted basis, is -$3.57. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of KalVista Pharmaceuticals (KALV) stock?

The operating margin for KalVista Pharmaceuticals (KALV) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of KalVista Pharmaceuticals (KALV) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of KalVista Pharmaceuticals (KALV) is -$154.72M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does KalVista Pharmaceuticals (KALV) have?

KalVista Pharmaceuticals (KALV) has a total debt of $6.25M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$25.6M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media